ERBB2 and breast cancer: Although lapatinib demonstrated that small molecule TKIs of HER2 have the potential to provide some intracranial control, a new generation of neratinib, tucatinib and other emerging HER2 TKIs, have replaced lapatinib in the treatment of HER2-positive BC, especially in patients with multi-line anti-HER2 resistance.